Guselkumab High-Dose vs Standard-Dose Study in Chinese Moderate-to-Severe Plaque Psoriasis

NIH added a new clinical trial registration for a Phase 4 interventional study comparing high-dose and extended-interval guselkumab dosing against standard dosing in Chinese adults with moderate-to-severe plaque psoriasis. The study will assess efficacy, safety, tolerability, and drug survival over the study period.

Healthcare providers and pharmaceutical companies conducting clinical research in China should note this trial for competitive intelligence and potential collaboration opportunities. The study's findings may inform future dosing recommendations for guselkumab in Asian populations, though this registration itself creates no compliance obligations.